Should You Buy GoodRx After Earnings?

Shares of GoodRx (NASDAQ: GDRX) are down nearly 17% from its IPO -- and at points in 2021 have fallen as much as 40%. However, I do not believe these results have been reflective of the company's financial performance in the year that it has been public. 

The company helps consumers cut costs on their prescriptions, offering free discount coupons that can be used at most pharmacies -- and savings of up to 80%. And those dollars and cents can certainly add up. Since its founding 10 years ago, GoodRx estimates that it has saved Americans $35 billion on prescriptions. So let's take a closer look at its prospects and why I believe it has a bright future ahead.

Image source: Getty Images.

Continue reading

Source Fool.com